Fresenius Medical Care publishes 2021 Global Annual Medical Report: Embracing the Complexity of Global Healthcare

WALTHAM, Mass., Sept. 23, 2021 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced publication of its 2021 Global Annual Medical Report. Titled "Embracing the Complexity of Global Healthcare," the report focuses on addressing healthcare complexities by driving meaningful advances in kidney disease care.

"The volume of thought leadership, ideas and expertise in the report demonstrates our company's continued leadership in kidney care, our innovation through lifelong learning and our commitment to our patient-centered mission," said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care.

The 2021 Global Annual Medical Report comprises 25 chapters by more than 40 authors from across the company. Six different sections each focus on a core theme of Fresenius Medical Care's Clinical & Quality Agenda. An additional COVID-19 section is dedicated to the company's ongoing efforts to address the pandemic.

The core themes are:

• Cardiovascular Health
• Precision Medicine
• Communication and Medical Education
• Global Research
• Patient-Centered Care
• Innovation and Transformation

The 2021 Global Annual Medical Report is published by the Global Medical Office of Fresenius Medical Care. The full report is now available online at: https://fmcna.com/insights/amr/

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 346,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Media Contact
Michael Gavin
T +49 6172 609-2978
[email protected]

Media Contact for North America
Brad Puffer
T +1 781-699-3331
[email protected]

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609-2601
[email protected]

www.freseniusmedicalcare.com

SOURCE Fresenius Medical Care Holdings, Inc.

Related Links

https://fmcna.com/